The combination of pembrolizumab andaxitinib (PAXI) is an approved first-line combination therapy for metastatic renal cell carcinoma (mRCC). A real-world study based out of Italy by Annalisa Guida, MD, and colleagues sought to evaluate the outcomes of this combination and uncover any relevant revelations of characteristic-based adverse events (AEs) for this immunotherapy combination. ...